JP Morgan Maintains Overweight on Cytokinetics, Lowers Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Tessa Romero maintains an Overweight rating on Cytokinetics (NASDAQ:CYTK) but lowers the price target from $77 to $65.
June 24, 2024 | 11:56 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan analyst Tessa Romero maintains an Overweight rating on Cytokinetics but lowers the price target from $77 to $65.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns or adjustments in expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100